Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

You May Also Be Interested In

• US Regulators Plan To Speed Authorizations Of New Vapes - WSJ
• CNA Financial (CNA) 2800 contracts of October 50 calls
• Proshares Trust Ultrashort Lehman 20+ Year Treasury (TBT) call put ratio 3.4 calls to 1 put 1